Explore

Trendline Trendline
Pharmaceutical Sector Faces Risks from Weight Loss Drug Boom

Pharmaceutical Sector Faces Risks from Weight Loss Drug Boom

Pharmaceutical Sector Faces Risks from Weight Loss Drug Boom
Trendline Trendline
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Injectable Demand

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Injectable Demand

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Injectable Demand
Reuters Reuters
US FDA approves Pfizer, Arvinas' breast cancer drug

US FDA approves Pfizer, Arvinas' breast cancer drug

By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an advanced form of the disease whose tumors carry a specific genetic mutation.
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
Trendline Trendline
Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment
Reuters Reuters
Big Pharma M&A set for mega year as patent expiries drive deal urgency

Big Pharma M&A set for mega year as patent expiries drive deal urgency

By Christy Santhosh and Sriparna Roy May 1 (Reuters) - Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial
Trendline Trendline
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Trendline Trendline
Scribe Therapeutics Showcases CRISPR Advances at ASGCT and EAS Congress 2026

Scribe Therapeutics Showcases CRISPR Advances at ASGCT and EAS Congress 2026

Scribe Therapeutics Showcases CRISPR Advances at ASGCT and EAS Congress 2026
Trendline Trendline
Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance

Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance

Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance
Trendline Trendline
Corcept Therapeutics' ALS Drug Shows Promising Survival Benefits as Phase 3 Trial Approaches

Corcept Therapeutics' ALS Drug Shows Promising Survival Benefits as Phase 3 Trial Approaches

Corcept Therapeutics' ALS Drug Shows Promising Survival Benefits as Phase 3 Trial Approaches